Edition:
India

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

24.45USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$24.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
348,065
52-wk High
$32.22
52-wk Low
$16.51

Select another date:

Fri, Dec 8 2017

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

BRIEF-Flexion Therapeutics announces pricing of public offering of common stock

* Flexion Therapeutics announces pricing of public offering of common stock

BRIEF-Flexion Therapeutics- Proposed public offering of 4 mln common shares

* Flexion Therapeutics announces proposed public offering of common stock

Flexion's knee pain drug gets FDA nod, shares hit life high

Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.

UPDATE 2-Flexion's knee pain drug gets FDA nod, shares hit life high

* Osteoarthritis drug market to hit $3.5 bln by 2026 - GlobalData

BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain

* Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain

Flexion's knee pain drug gets FDA nod

Oct 6 Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

* Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

BRIEF-Flexion Therapeutics qtrly loss per share $0.91

* Flexion therapeutics reports second quarter 2017 financial results and recent business highlights

Select another date: